clinical trial · NCT05169424
A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
Boehringer Ingelheim·—·completed·n = 9,117
Pulmonary Disease, Chronic ObstructiveTrelegy ElliptaStiolto RespimatTiotropium + Olodaterol (5/5 mcg)Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
brief summary
This study looks at data from people with chronic obstructive pulmonary disease (COPD). Some used Stiolto Respimat and the others Trelegy Ellipta as their first treatment for COPD. The purpose of this study is to find out how well the treatments worked. Researchers compare the time to first COPD flare-up (exacerbation) between the 2 treatments. The study analyses anonymous data from pharmacy claims collected over 3.5 years.
started
Dec 17, 2021
primary completion
Dec 27, 2021
completion
Dec 27, 2021
last updated
Oct 19, 2023
official title
Comparison of Exacerbation Risk and Health Outcomes in Maintenance Treatment naïve Chronic Obstructive Pulmonary Disease (COPD) Patients Using Stiolto Versus Trelegy, a Real-World Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol